Results 51 to 60 of about 189,690 (343)

Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]

, 2017
Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz, Efraín A. Gómez, Felipe Martinez, Felix Ramires, Jean L. Rouleau, John J.V. McMurray, Karl Swedberg, Kenneth Dickstein, Lars Køber, Li Shen, Luis Eduardo Echeverría, Luiz Carlos Bodanese, Michael R. Zile, Milton Packer, null null, Pardeep S. Jhund, Scott D. Solomon, William T. Abraham   +17 more
core   +3 more sources

GAMBARAN PERESEPAN OBAT BETA BLOCKER PADA PASIEN GAGAL JANTUNG SISTOLIK YANG DIRAWAT JALAN DI RSUP DR. KARIADI SEMARANG

Jurnal Kedokteran Diponegoro, 2018
Latar Belakang: Gagal jantung sistolik merupakan kegagalan jantung untuk memberikan suplai darah dalam memenuhi kebutuhan metabolisme jaringan dengan hipertrofi dinding ventrikel yang memiliki output terbatas karena ejeksi yang terganggu selama sistol ...
Monica Destiani, Ilham Uddin, Pipin Ardhianto   +2 more
doaj   +1 more source

The anti‐CRISPR protein AcrIE8.1 inhibits the type I‐E CRISPR‐Cas system by directly binding to the Cascade subunit Cas11

FEBS Letters, EarlyView.
In this study, we present the structure of AcrIE8.1, a previously uncharacterized anti‐CRISPR protein that inhibits the type I‐E CRISPR‐Cas system. Through a combination of structural and biochemical analyses, we demonstrate that AcrIE8.1 directly binds to the Cas11 subunit of the Cascade complex to inhibit the CRISPR‐Cas system.
Young Woo Kang, Hyun Ho Park
wiley   +1 more source

Influence of Beta Blockers on Survival in Dogs with Severe Subaortic Stenosis

Journal of Veterinary Internal Medicine, 2014
Background Subaortic stenosis (SAS) is one of the most common congenital cardiac defects in dogs. Severe SAS frequently is treated with a beta adrenergic receptor blocker (beta blocker), but this approach largely is empirical.
B.D. Eason, D.M. Fine, D. Leeder, C. Stauthammer, K. Lamb, A.H. Tobias   +5 more
doaj   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

The Caenorhabditis elegans DPF‐3 and human DPP4 have tripeptidyl peptidase activity

FEBS Letters, EarlyView.
The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
wiley   +1 more source

Perioperative beta-blocker and its effect on coronary artery bypass graft patients outcome after surgery

Ain Shams Journal of Anesthesiology, 2020
Background Beta-adrenergic receptor blockers have been studied for minimizing the effects of catecholamines by blocking their activation of beta receptors.
Mohamed N. Elshafei, Wael Reda Hussein, Oliver M. Shehata, Mohamed A. Tolba   +3 more
doaj   +1 more source

Crosstalk between the ribosome quality control‐associated E3 ubiquitin ligases LTN1 and RNF10

FEBS Letters, EarlyView.
Loss of the E3 ligase LTN1, the ubiquitin‐like modifier UFM1, or the deubiquitinating enzyme UFSP2 disrupts endoplasmic reticulum–ribosome quality control (ER‐RQC), a pathway that removes stalled ribosomes and faulty proteins. This disruption may trigger a compensatory response to ER‐RQC defects, including increased expression of the E3 ligase RNF10 ...
Yuxi Huang, Satoshi Hashimoto, Sota Ito, Chisato Kikuguchi, Miho Hoshi, Kiyoshi Yamaguchi, Yoichi Furukawa, Toru Suzuki, Toshifumi Inada   +8 more
wiley   +1 more source

Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients

Journal of Emergencies, Trauma and Shock, 2014
Purpose: Trauma dogma dictates that the physiologic response to injury is blunted by beta-blockers and other cardiac medications. We sought to determine how the pre-injury cardiac medication profile influences admission physiology and post-injury ...
David C Evans, Kendrick M Khoo, Andrei Radulescu, Charles H Cook, Anthony T Gerlach, Thomas J Papadimos, Steven M Steinberg, Stanislaw PA Stawicki, Daniel S Eiferman   +8 more
doaj   +1 more source

Maternal beta‐blocker dose and risk of small‐for gestational‐age in women with heart disease

Acta Obstetricia et Gynecologica Scandinavica, 2022
Introduction Beta‐blockers are prescribed for many pregnant women with heart disease, but whether there is a dose‐dependent effect on fetal growth remains to be examined. We aimed to investigate if antenatal beta‐blocker use and dose were associated with
Ingvil Krarup Sørbye, Randi Haualand, Henriette Wiull, Anne‐Sofie Letting, Eldrid Langesæter, Mette‐Elise Estensen   +5 more
doaj   +1 more source